Patient characteristics
Patient no. . | Leukemia type . | Karyotype . |
|---|---|---|
| 1 | CML - blast crisis | 46, XY, t(9;22) (q34;q11.2)[20] |
| 2 | AML-M1 | No metaphases |
| 3 | AML-M0 | 47,XY,+8[15]/46XY[5] |
| 4 | AML-M2, | 46,XY,del(9)(q21.2q32)[8]/46XY[12] |
| 5 | AML-M4 | 46,Y,add(X)(p22),add(2)(q12),del(3)(q22),add(10)(q21)[20] |
| 6 | AML-M5 | 46,XY,inv (16)(p13 q22)[5]/47,idem,+8[18] |
| 7 | AML-M4 | 46,XX,inv(16)(p13q22)[9]/46,XX[11] |
| 8 | AML-M1 | 46 XX[20] |
| 9 | AML-M3 | 46,XY,t(15:17)(Q22;21)[20] |
| 10 | AML-M0 | 46,XX[20] |
| 11 | AML-M2 | 56-57, XX, +1, +2, del(4)(q31), del (5)(q13)(q33)×2 +6, +9, +11, +13, +14, +15, +22[CP20] |
| 12 | AML-M4 | 46,XX,del(11)(q23)[15]/46XX[5] |
| 13 | AML-M4 | 46XX,inv(16)(p13q22)[20] |
Patient no. . | Leukemia type . | Karyotype . |
|---|---|---|
| 1 | CML - blast crisis | 46, XY, t(9;22) (q34;q11.2)[20] |
| 2 | AML-M1 | No metaphases |
| 3 | AML-M0 | 47,XY,+8[15]/46XY[5] |
| 4 | AML-M2, | 46,XY,del(9)(q21.2q32)[8]/46XY[12] |
| 5 | AML-M4 | 46,Y,add(X)(p22),add(2)(q12),del(3)(q22),add(10)(q21)[20] |
| 6 | AML-M5 | 46,XY,inv (16)(p13 q22)[5]/47,idem,+8[18] |
| 7 | AML-M4 | 46,XX,inv(16)(p13q22)[9]/46,XX[11] |
| 8 | AML-M1 | 46 XX[20] |
| 9 | AML-M3 | 46,XY,t(15:17)(Q22;21)[20] |
| 10 | AML-M0 | 46,XX[20] |
| 11 | AML-M2 | 56-57, XX, +1, +2, del(4)(q31), del (5)(q13)(q33)×2 +6, +9, +11, +13, +14, +15, +22[CP20] |
| 12 | AML-M4 | 46,XX,del(11)(q23)[15]/46XX[5] |
| 13 | AML-M4 | 46XX,inv(16)(p13q22)[20] |
Patient leukemia cell types were classified according to the FAB classification system.16